gutflix
GI learning, personalised

Summary

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN'S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Nicola Imperatore

UEG Week Copenhagen 2023 | Poster

IBD

October 16, 2023

A multicenter retrospective cohort study of 577 perianal Crohn's disease patients from 22 hospitals in 13 countries found ustekinumab demonstrated superior clinical response and remission rates compared to vedolizumab or anti-TNFs as 2nd or 3rd line biological therapy.

KEY POINTS

- In 2nd line treatment for active perianal Crohn's disease, ustekinumab showed significantly higher clinical response (aOR 7.2, 95%CI 3.23-16.06, p<0.001) and remission (aOR 2.2, 95%CI 1.1-4.6, p=0.04) compared to propensity-matched anti-TNF and vedolizumab cases.
- In 3rd line treatment for active disease, ustekinumab showed significantly higher clinical response (aOR 5.1, 95%CI 2.4-10.6, p<0.001) and remission (aOR 2.73, 95%CI 1.2-10.64, p<0.001) compared to anti-TNF and vedolizumab.
- For patients with inactive disease at 3rd line initiation, ustekinumab had significantly lower rates of perianal disease recurrence (aOR 0.17, 95%CI 0.04-0.76, p=0.02) compared to anti-TNF and vedolizumab.
- Radiological evidence showed 63% of ustekinumab-treated patients had fistula improvement on MRI or TRUS in 2nd line, compared to 37% with vedolizumab and 59% with anti-TNF (p=0.01).
- The authors note results merit validation in a prospective study; clinicians managing refractory perianal Crohn's disease would benefit from reviewing this comparative effectiveness data.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/5d915db8-743c-11ee-a311-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.